In addition to the heterozygosity of cells within a tumor, stem cells have been another factor owing to the chemotherapy resistance of cancer. The dispute over stem cell’s contribution to tumor proliferation has ranged from partial influence to complete attribution. The hope is that if the true malignant potential of stem cells is defined, then attacking this malevolent group of cells will lead to better prognoses and treatments. Similar to the thirst of deducing what were the genetic materials in the mid-1900s, a breakthrough here could lead to a number of advancements in its respective field.
Although the stem cell theory has been extensively studied and partially approved, the emergence of a range of consistent stem cell markers to assist in diagnosis has not been well established. In order to conduct better research on this subpopulation of cells and come closer to an answer, a dependable way of isolating and recognizing them is necessary.CD133 is a transmembranous protein and has been found to a stem cell marker. CD133 as a prognostic factor has been found in cancer stem cells of several organs such as pancreas, breast, stomach and gallbladder.